



Neal, D. E., Metcalfe, C., Donovan, J. L., Lane, J. A., Davis, M. J., Young, G. J., Dutton, S. J., Walsh, E. I., Martin, R. M., Peters, T. J., Turner, E. L., Mason, M., Bollina, P., Catto, J., Doherty, A., Gillatt, D., Gnanapragasam, V., Holding, P., Hughes, O., ... Hamdy, F. C. (2020). Ten-year mortality, disease progression and treatment-related side-effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. *European Urology*, 77(3), 320-330. <https://doi.org/10.1016/j.eururo.2019.10.030>

Publisher's PDF, also known as Version of record

License (if available):  
CC BY

Link to published version (if available):  
[10.1016/j.eururo.2019.10.030](https://doi.org/10.1016/j.eururo.2019.10.030)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the final published version of the article (version of record). It first appeared online via Elsevier at <https://www.sciencedirect.com/science/article/pii/S0302283819308371>. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/pure/user-guides/explore-bristol-research/ebr-terms/>

**Supplementary Table 1: Full Gleason Group distribution for randomised and treatment choice cohorts**

| <b>Cohort</b>        | AM       | RP       | RT       |
|----------------------|----------|----------|----------|
| <b>Gleason group</b> | n (%)    | n (%)    | n (%)    |
| Randomised           | N=628    | N=488    | N=491    |
| 1                    | 503 (80) | 366 (75) | 370 (75) |
| 2                    | 95 (15)  | 95 (19)  | 79 (16)  |
| 3                    | 21 (3.3) | 17 (3.5) | 27 (5.5) |
| 4                    | 8 (1.3)  | 8 (1.6)  | 11 (2.2) |
| 5                    | 1 (0.16) | 2 (0.41) | 4 (0.81) |
| Treatment choice     | N=507    | N=262    | N=189    |
| 1                    | 417 (82) | 186 (71) | 123 (65) |
| 2                    | 73 (14)  | 58 (22)  | 52 (28)  |
| 3                    | 15 (3.0) | 9 (3.4)  | 7 (3.7)  |
| 4                    | 2 (0.39) | 7 (2.7)  | 5 (2.6)  |
| 5                    | 0        | 2 (0.76) | 2 (1.1)  |

**Supplementary Table 2:** Event counts (rates per 1000 person-years) by treatment received group and Gleason grade group

|                                     | Treatment received group   |                            |                            |
|-------------------------------------|----------------------------|----------------------------|----------------------------|
|                                     | AM                         | RP                         | RT                         |
| <b>Gleason Grade Group 1</b>        | N=920<br>8757 person-years | N=552<br>5260 person-years | N=493<br>4795 person-years |
| Prostate cancer death               | 8 (0.9)                    | 1 (0.2)                    | 3 (0.6)                    |
| Prostate cancer metastases or death | 31 (3.5)                   | 5 (1.0)                    | 9 (1.9)                    |
| Non-curative hormone therapy        | 48 (5.5)                   | 9 (1.7)                    | 14 (2.9)                   |
| <i>None of the above</i>            | <b>865</b>                 | <b>540</b>                 | <b>479</b>                 |
| <b>Gleason Grade Group 2</b>        | N=168<br>1500 person-years | N=153<br>1341 person-years | N=131<br>1196 person-years |
| Prostate cancer death               | 8 (5.3)                    | 3 (2.2)                    | 1 (0.8)                    |
| Prostate cancer metastases or death | 24 (16)                    | 6 (4.5)                    | 7 (5.9)                    |
| Non-curative hormone therapy        | 23 (15)                    | 13 (9.7)                   | 13 (11)                    |
| <i>None of the above</i>            | <b>136</b>                 | <b>137</b>                 | <b>118</b>                 |
| <b>Gleason Grade Group 3-5</b>      | N=47<br>379 person-years   | N=45<br>426 person-years   | N=56<br>504 person-years   |
| Prostate cancer death               | 5 (13)                     | 1 (2.3)                    | 1 (2.0)                    |
| Prostate cancer metastases or death | 9 (24)                     | 7 (16)                     | 2 (3.7)                    |
| Non-curative hormone therapy        | 12 (32)                    | 11 (26)                    | 9 (18)                     |

---

*None of the above*

32

33

47

---

**Supplementary Table 3: EPIC item: One or more pads per day in the past 4 weeks**

|           | AM     |        | RP      |        | RT     |       | p-value |
|-----------|--------|--------|---------|--------|--------|-------|---------|
|           | n/N    | (%)    | n/N     | (%)    | n/N    | (%)   |         |
| Baseline  | 0/563  | (0)    | 3/354   | (0.84) | 0/312  | (0)   |         |
| 6 months  | 2/717  | (0.28) | 272/492 | (55)   | 6/448  | (1.3) |         |
| 12 months | 4/740  | (0.54) | 164/508 | (32)   | 7/460  | (1.5) |         |
| 24 months | 23/828 | (2.8)  | 134/562 | (24)   | 12/504 | (2.4) |         |
| 36 months | 29/901 | (3.2)  | 143/609 | (23)   | 10/544 | (1.8) |         |
| 48 months | 45/942 | (4.8)  | 122/618 | (20)   | 12/567 | (2.1) |         |
| 60 months | 48/970 | (4.9)  | 123/619 | (20)   | 13/589 | (2.2) |         |
| 72 months | 66/948 | (7.0)  | 127/619 | (21)   | 13/567 | (2.3) | <0.001  |

**Supplementary Table 4: ICSmaleSF nocturia item: twice or more per night**

|           | AM      |      | RP      |      | RT      |      | p-value |
|-----------|---------|------|---------|------|---------|------|---------|
|           | n/N     | (%)  | n/N     | (%)  | n/N     | (%)  |         |
| Baseline  | 201/985 | (20) | 146/650 | (22) | 114/581 | (20) |         |
| 6 months  | 236/971 | (24) | 225/646 | (35) | 388/598 | (65) |         |
| 12 months | 223/981 | (23) | 168/645 | (26) | 217/596 | (36) |         |
| 24 months | 275/978 | (28) | 150/645 | (23) | 193/606 | (32) |         |
| 36 months | 304/995 | (31) | 158/644 | (25) | 190/586 | (32) |         |
| 48 months | 320/984 | (33) | 160/648 | (25) | 193/589 | (33) |         |
| 60 months | 347/982 | (35) | 147/637 | (23) | 214/595 | (36) |         |
| 72 months | 363/968 | (38) | 156/635 | (25) | 198/576 | (34) | <0.001  |

**Supplementary Table 5: EPIC item: Erections firm enough for intercourse**

|           | AM      |      | RP      |       | RT      |      | p-value |
|-----------|---------|------|---------|-------|---------|------|---------|
|           | n/N     | (%)  | n/N     | (%)   | n/N     | (%)  |         |
| Baseline  | 370/548 | (68) | 229/345 | (66)  | 196/312 | (63) |         |
| 6 months  | 415/698 | (59) | 25/490  | (5.1) | 81/439  | (18) |         |
| 12 months | 433/716 | (60) | 28/502  | (5.6) | 154/450 | (34) |         |
| 24 months | 437/807 | (54) | 73/552  | (13)  | 159/491 | (32) |         |
| 36 months | 436/882 | (49) | 86/600  | (14)  | 179/533 | (34) |         |
| 48 months | 397/918 | (43) | 93/624  | (15)  | 173/555 | (31) |         |
| 60 months | 374/943 | (40) | 99/625  | (16)  | 166/584 | (28) |         |
| 72 months | 325/938 | (35) | 93/624  | (15)  | 162/566 | (29) | <0.001  |

**Supplementary Table 6: EPIC item: Bloody stools about half the time or more frequently**

|           | AM     |        | RP     |        | RT     |       | p-value |
|-----------|--------|--------|--------|--------|--------|-------|---------|
|           | n/N    | (%)    | n/N    | (%)    | n/N    | (%)   |         |
| Baseline  | 7/559  | (1.3)  | 3/356  | (0.84) | 4/314  | (1.3) |         |
| 6 months  | 9/722  | (1.2)  | 3/495  | (0.61) | 16/451 | (3.5) |         |
| 12 months | 8/738  | (1.1)  | 2/511  | (0.39) | 17/462 | (3.7) |         |
| 24 months | 4/834  | (0.48) | 4/570  | (0.70) | 36/505 | (7.1) |         |
| 36 months | 8/906  | (0.88) | 7/612  | (1.1)  | 44/546 | (8.1) |         |
| 48 months | 12/953 | (1.3)  | 6/630  | (1.0)  | 43/569 | (7.6) |         |
| 60 months | 16/980 | (1.6)  | 6/639  | (0.94) | 46/595 | (7.7) |         |
| 72 months | 11/968 | (1.1)  | 10/644 | (1.6)  | 34/574 | (5.9) | <0.001  |